Mirati Therapeutics

Youtube Subscribe

Open: 43.71 Close: 43.62 Change: -0.09

The top 10 things about Mirati Therapeutics found by an AI.

This document will help you to evaluate Mirati Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Mirati Therapeutics are: Mirati, Therapeutics, therapeutic, stock, Inc, see, increase, …

Concept Map

Semantic Network

Stock Summary

Mirati Therapeutics, Inc. provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC).

Today's Summary

Mirati Therapeutics Inc (MRTX) shares moved 1.2% today (38% likelihood event) [4/27/23]

Today's News

Mirati Therapeutics, Inc. sees increase in short interest during march while focusing on novel cancer therapeutics - best stocks. mirati therapeutics, inc. sees increased in short. interest during March. Despite opening at $41.10 on June 11 June 2021 – well below its 12-month high. Mirati Therapeutics Inc (MRTX) shares moved 1.2% today (38% likelihood event) [4/27/2023] Mirati therapeutics (mrtx) Shares Moved 1,2% Today. (1.23%) Today Watchers 3,873 $43.62 $0.53 (123%) Sentiment 8.33% Mirati Therapeutics (NASDAQ: MRTX) stock is rising on Thursday as investors react to a special designation from the FDA. Miratis lung cancer drug gets an accelerated approval. StockNews.com started coverage on shares of Mirati Therapeutics in a report on Thursday, March 16th. The stock has an average rating of “Hold” and an average price target of $80.87. According to data from MarketBeat.com, Mirati.

Stock Profile

"Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California."

Keywords

How much time have you spent trying to decide whether investing in Mirati Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Mirati Therapeutics are: Mirati, Therapeutics, therapeutic, stock, Inc, see, increase, and the most common words in the summary are: therapeutic, mirati, inc, market, stock, cancer, disease, . One of the sentences in the summary was: Mirati Therapeutics Inc (MRTX) shares moved 1.2% today (38% likelihood event) [4/27/23]. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #mirati #inc #market #stock #cancer #disease.

Read more →

Youtube Subscribe

---